JTJonathan Tibballs

Jonathan Tibballs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan Tibballs has a total of 291 co-authors. Here are the top co-authors by number of shared publications:

  • Shaun Samuelson

    Department of Interventional Radiology Sir Charles Gardiner Hospital Nedlands Western Australia Australia

    7 shared publications
  • David Patch

    The Sheila Sherlock Hepatobiliary-Pancreatic and Liver Unit Royal Free Hospital London United Kingdom

    6 shared publications
  • John Ferguson

    Department of Radiology Sir Charles Gairdner Hospital Perth Western Australia Australia

    6 shared publications
  • Anthony Watkinson

    5 shared publications
  • George Garas

    Department of Hepatology Sir Charles Gairdner Hospital Perth Western Australia Australia

    5 shared publications
  • Gerry MacQuillan

    Department of Hepatology Sir Charles Gairdner Hospital Perth Western Australia Australia

    5 shared publications

Latest Publications

  • Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation for the Treatment of Early‐Stage Hepatocellular Carcinoma

    by Darragh Egan, Fadak Mohammadi, Lauren Brotherton, William Ormiston, Jonathan Tibballs, Shaun Samuelson, Luis Calzadilla Bertot, Hien Le, Colin Tang, Michael Wallace, et al.

    Background: Stereotactic ablative body radiotherapy (SABR) shows promise as curative therapy for early‐stage hepatocellular carcinoma (HCC). We retrospectively assessed the efficacy of SABR and microwave ablation (MWA) in a multi‐centre Australian cohort, comparing local recurrence (LR), mortality, and toxicity. Methods: This was a retrospective cohort study of 215 early stage HCC tumours treated with SABR across 4 referral centres. Cohort comparison was made to single centre data of MWA in 121 tumours. Results: The main aetiologies of liver disease were hepatitis C and alcohol. The SABR cohort had higher prior HCC treatment (70% vs. 48%; p < 0.001), and more tumours > 2 cm (58% vs. 40%; p = 0.002). LR in the SABR cohort were 4.9% and 6.2% at 1 and 2 years respectively. LR rates in the MWA cohort were 12.4% and 17.3% at 1 and 2 years respectively ( p = 0.006). After adjustment for age, sex, MELD, previous HCC treatment, tumour size, and AFP, the SABR cohort had reduced risk of LR compared to MWA (aHR 0.24; 95% CI 0.1–0.58, p = 0.001). Survival was higher in the MWA cohort to the SABR cohort ( p < 0.001) despite higher rates of LR. Treatment related complications were common, but mild. Serious adverse events (AE) were rare in both groups. Conclusion: SABR demonstrated reduced LR compared to MWA in HCC tumours > 2 cm. The worse survival rates in the SABR cohort may reflect patient factors independent of HCC. Our study findings provide further justification for randomised‐controlled trials investigating SABR as primary treatment for early‐stage HCC.

  • Open Access

    The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus

    by Avik Majumdar, Jacinta Holmes, Stuart K. Roberts, Purnima Bhat, Tim Mitchell, Jeyamani Ramachandran, James O’BEirne, Sarah Walker, Rohit Sawhney, Nishita Jagarlamudi, et al.

    Background: In Australia, chronic liver disease is now the third leading cause of premature death in people aged 50–59 years, and the fourth leading cause in all other 5-year age groups from 35 to 70 years in Australia. A consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis was developed by the Gastroenterological Society of Australia (GESA), the peak national organization for health care professionals and researchers working in gastroenterology and hepatology, to provide contemporary, evidence-based clinical guidelines. A summary of its recommendations is presented here. Methods: The consensus statement was developed in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument and the 2016 National Health and Medical Research Council Standards for Guidelines. A panel of 46 health care professionals with expertise in managing portal hypertension participated in the development of the consensus statement. The consensus development conference method was used to determine consensus for each recommendation, with a hybrid face-to-face and online meeting held in Noosa, Australia, on 3 August 2024, followed by 2 online meetings. Results: A total of 52 recommendations were approved by the consensus development group without dissent across the following domains: (1) diagnosis, risk stratification, and prevention of decompensation; (2) portal hypertension–related bleeding; (3) ascites and renal impairment; (4) hepatic encephalopathy; (5) sarcopenia, nutrition, and frailty; (6) thrombosis in cirrhosis; (7) cardiopulmonary complications; (8) surgery and portal hypertension; and (9) pregnancy and portal hypertension. Discussion: This is the first Australian consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis. The recommendations in this summary document provide standardized clinical guidance with the goal of improving outcomes for patients with cirrhosis and portal hypertension in Australia.


  • Open Access

    Loss of both diffusion restriction and arterial enhancement can predict complete pathological response following Y-90 selective internal radiation therapy for hepatocellular carcinoma

    by Kah Heng Alexander Lim, Matthew Joel Clifford, William Ormiston, Tze Sheng Khor, Khanh Quoc Steven Ngo, Alistair Rowcroft, Lingjun Mou, Luc Delriviere, Michael Wallace, Mayank Bhandari, et al.

    Purpose: To assess the association of diffusion restriction on diffusion weighted MRI (DWI) with complete pathological necrosis (CPN) in hepatocellular carcinoma (HCC) following selective internal radiation therapy with Yttrium-90 resin microspheres (SIRT). Methods: A retrospective cohort study of patients undergoing resection or transplantation for HCC following SIRT was performed. Imaging pre- and post-SIRT was assessed for response to treatment via mRECIST and for the presence of diffusion restriction on DWI. Histological specimens were assessed for complete pathological necrosis (CPN). Results: Twenty-nine tumours were included from 25 patients; mRECIST complete response (CR) demonstrated moderate reliability (sensitivity 0.92, specificity 0.68) for predicting CPN. Twelve tumours did not have diffusion restriction on pretreatment DWI; following their exclusion, loss of diffusion restriction demonstrated a weak agreement (sensitivity 0.85, specificity 0.80, Cohen’s Kappa 0.197) for prediction of CPN. The combination of mRECIST CR and loss of diffusion restriction was associated with CPN in 100% (6/6) cases; whilst persistent abnormal diffusion restriction despite mRECIST CR was associated with residual disease in 75% (3/4) cases. Conclusion: The combination of mRECIST CR when combined with loss of diffusion restriction appears to predict CPN post SIRT; persistent diffusion restriction despite the findings of mRECIST CR appears to correlate with residual disease.

  • Safety and Efficacy of Selective Internal Radiation Therapy for Portal Vein Tumour Thrombus in Advanced Hepatocellular Carcinoma: A Single‐Centre Experience in Australia

    by William Ormiston, Shaun Samuelson, Matthys Van Wyk, Luis Calzadilla‐Bertot, Briohny Smith, George Garas, Gerry MacQuillan, Leon A. Adams, Gary P. Jeffrey, Michael Wallace, et al.

    Introduction: Portal vein tumour thrombus (PVTT) is a common complication of hepatocellular carcinoma (HCC) and has a poor prognosis. Selective internal radiation therapy (SIRT) with Yttrium‐90 (Y90) microspheres is a minimally invasive treatment option that has shown promise in treating PVTT. Studies have suggested a survival advantage of SIRT in this population, but data in the Australasian population are lacking. The aim of this study was to evaluate the safety and efficacy of SIRT in a series of patients at an Australian hospital with advanced HCC and PVTT.Method: All patients underwent pre‐treatment imaging with MRI or CT, and immediate post‐treatment imaging with Y90 PET CT and MRIs at 3‐, 6‐, 9‐ and 12‐months. The primary endpoints were time to progression (TTP) and overall survival (OS) post‐SIRT. The secondary endpoint was safety.Results: Of the 698 patients who underwent SIRT at our institution between 2007 and 2023, 64 patients had HCC and PVTT. 59/64 (92%) were male, with a median age of 61 years (range 37–86 years). The majority of patients had Child–Pugh a cirrhosis (87%), and the majority were ECOG 0 (91%). The majority had main PVTT at the time of SIRT. All patients underwent SIRT with Y90‐coated resin microspheres (SIR‐Spheres, Sirtex Medical, Australia). Personalised dosimetry planning was performed by the treating interventional radiologist. SIRT was well tolerated by most patients, with major complications reported in a minority of cases (19/64 patients had an episode of biochemical decompensation within 90 days following treatment). The median TTP was 4.8 months (range 1–48 months). The median OS was 11.5 months (range 1–80 months), with those with a favourable MAAPE score having a median OS of 21.2 months (12.6–29.7 months).Conclusions: Our cohort suggests that SIRT is a safe and effective treatment option for a difficult‐to‐treat patient population. Our data suggest a longer OS for those with preserved liver function, good functional status and low AFP levels at 21.2 months. Poor pre‐treatment liver function and functional status are predictors of decompensation, and decompensation is a predictor of poor survival. These data provide an Australasian perspective and support the expanding role of SIRT in HCC treatment guidelines. Further prospective studies with larger sample sizes and longer follow‐up are warranted to confirm these findings.


  • Top Cited Papers

    FBP1 controls liver cancer evolution from senescent MASH hepatocytes

    by Li Gu, Yahui Zhu, Shuvro P. Nandi, Maiya Lee, Kosuke Watari, Breanna Bareng, Masafumi Ohira, Yuxiao Liu, Sadatsugu Sakane, Rodrigo Carlessi, et al.

    Hepatocellular carcinoma (HCC) originates from differentiated hepatocytes undergoing compensatory proliferation in livers damaged by viruses or metabolic-dysfunction-associated steatohepatitis (MASH)1. While increasing HCC risk2, MASH triggers p53-dependent hepatocyte senescence3, which we found to parallel hypernutrition-induced DNA breaks. How this tumour-suppressive response is bypassed to license oncogenic mutagenesis and enable HCC evolution was previously unclear. Here we identified the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) as a p53 target that is elevated in senescent-like MASH hepatocytes but suppressed through promoter hypermethylation and proteasomal degradation in most human HCCs. FBP1 first declines in metabolically stressed premalignant disease-associated hepatocytes and HCC progenitor cells4,5, paralleling the protumorigenic activation of AKT and NRF2. By accelerating FBP1 and p53 degradation, AKT and NRF2 enhance the proliferation and metabolic activity of previously senescent HCC progenitors. The senescence-reversing and proliferation-supportive NRF2–FBP1–AKT–p53 metabolic switch, operative in mice and humans, also enhances the accumulation of DNA-damage-induced somatic mutations needed for MASH-to-HCC progression.


  • Percutaneous microwave ablation of T1a renal cell carcinomas: A 10‐year single‐center retrospective review

    by Cassie McCloskey, Angela Jacques, Dylan McCloskey, Jonathan Tibballs

    Introduction: Partial nephrectomy is currently the preferred treatment option for T1a renal cell carcinomas (RCC), with nephron‐sparing techniques, including microwave ablation, becoming more common in select patients. Primary aims are to document outcomes of microwave ablation for T1a RCCs in an Australian tertiary centre to add to the evidence for its safety and efficacy.Methods: The prospectively maintained Sir Charles Gairdner Hospital Interventional Radiology database was retrospectively searched for all Renal Microwave ablations completed between June 2012 and February 2022. This database and a combination of hospital programmes including Agfa Impax PACS, Bossnet digital medical record and iSoft Clinical Manager were used to extract the relevant data which was anonymized and entered into an Excel spreadsheet for analysis.Results: Forty‐eight patients underwent microwave ablation for 50 tumours. Of these, there were two local and two distant recurrences. A fifth patient had metastases on presentation. Higher local recurrence rates were associated with larger tumour size (P = 0.043). Tumour proximity to the collecting system P = 0.020). RENAL scores did not show statistically significant correlation with complications (P = 0.092) or local or distant recurrence. Notably, the study follow‐up time was longer than many comparative studies (mean = 2796, ~7.66 years censoring for death and mean = 832 days, ~2.28 years not censoring for death).Conclusion: Consistent with the literature, this study further demonstrates that microwave ablation is a safe and efficacious option for treatment of T1a RCC.


  • Sutton–Kadir Syndrome can be treated safely with endovascular embolisation alone

    by Rama Chidambaram, Julian Soares, Rhiannon Hicks, Shaun Samuelson, Jonathan Tibballs, John Ferguson, Shirley Jansen

    Introduction: Sutton–Kadir Syndrome (SKS) describes true inferior pancreaticoduodenal artery (IPDA) aneurysms in the setting of coeliac artery (CA) stenosis or occlusion. Although rare, SKS aneurysms can rupture and cause morbidity. Due to its rarity and lack of controlled treatment data, correct treatment for the CA lesion is currently unknown. Our aim was to assess if endovascular embolisation alone was safe and effective in treatment of SKS aneurysms, in emergent and elective settings. Secondary objectives were to describe presentation and imaging findings.Methods: A retrospective cohort study of patients treated at Sir Charles Gairdner Hospital between January 2014 and December 2021 was done. Data on presentation, diagnostics, aneurysm characteristics, CA lesion aetiology, treatment and outcomes were extracted from chart review.Results: Twenty‐four aneurysms in 14 patients were identified. Rupture was seen in 7/15 patients. Most aneurysms (22/24) were in the IPDA or one of its anterior or posterior branches. Median arcuate ligament (MAL) compression was identified in all. There was no difference in median (IQR) maximal transverse diameter between ruptured and non‐ruptured aneurysms (6 mm (9), 12 mm (6), P = 0.18). Of ruptures, 6/7 had successful endovascular embolisation and 1/7 open surgical ligation. Of non‐ruptures, 6/7 had successful endovascular embolisation, 1/7 open MAL division then endovascular CA stenting and aneurysm embolisation. No recurrences or new aneurysms were detected with computed tomography or magnetic resonance angiography over a median (IQR) follow‐up period of 30 (10) months in 12 patients.Conclusion: Endovascular embolisation of SKS aneurysms without treatment of MAL compression is safe and effective in both the emergent and elective settings.


  • Open Access

    Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment?

    by Jonathan Tibballs, Warren Clements

    Hepatocellular carcinoma (HCC) is the fourth most common cancer worldwide and its incidence is increasing in Australia. Transarterial therapy, predominantly transarterial chemoembolization (TACE) but increasingly transarterial radioembolization (TARE), plays an important role in patients with intermediate‐stage disease and preserved liver function. However, despite advances in TACE, TARE and adjunctive procedures, overall survival has only modestly increased over the last 20 years. Immunotherapy has emerged as a newer cancer treatment and uses antibodies directed at checkpoint inhibitors to upregulate T‐cell mediated tumour‐specific death. These drugs have been shown to increase survival in patients with HCC and have changed the landscape for advanced disease. Trials are now ongoing combining transarterial therapy and immunotherapy. This manuscript introduces these trials and interventional radiologists should be aware of the changing landscape so that they can partner with immunotherapy and remain relevant in the HCC multidisciplinary group as immunotherapy use increases.


  • Open Access

    Long-Term Outcomes of the Flixene Vascular Graft Used for Haemodialysis

    by Bulang He, Duxxa Taylor, Zi Qin Ng, Shaun Samuelson, Sanjay Nadkarni, Matt Van Myk, John Ferguson, Jonathan Tibballs, Doris Chan

    Introduction The Flixene™ vascular graft (Maquet-Atrium Medical, Hudson, NH) has emerged as a new generation synthetic graft, which allows for early needling for haemodialysis. Most studies have shown satisfactory early results. The aim of this study is to report on long-term outcomes of the Flixene graft over eight years in a cohort of patients. Methods From February 2011 to September 2019, 61 patients had 64 arteriovenous graft fistulas (AVGs) by using the Flixene grafts. The median patient age was 67 years; the male to female ratio was 30:31. Diabetes was the reason for the majority of kidney failures (57%). The configuration of the grafts used was mostly upper arm straight AVG. The primary patency rate, secondary patency rate, and surgical complications were assessed. Results In a median follow-up of three years (interquartile range (IQR): 2 - 6), 36 of the AVGs required a fistulogram. Venous side stenosis was the most common cause of high venous pressure or AVG occlusion in 97%. The one-year primary patency rate was 30%. The secondary patency rate was 94.8%, 83.7%, and 77.7% at one, three, and five years, respectively. The longest functional AVG was observed for up to seven years. Conclusions This study has shown satisfactory long-term results of the Flixene graft used for hemodialysis. The Flixene graft could be needled within 72 hours without increased complications, which allows the creation of an AVG under an emergency setting to avoid the placement of a central venous catheter (CVC). This strategy should be advocated in future clinical practice.


  • Ad Libitum Mediterranean and Low‐Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial

    by Catherine Properzi, Therese A. O'SUllivan, Jill L. Sherriff, Helena L. Ching, Garry P. Jeffrey, Rachel F. Buckley, Jonathan Tibballs, Gerry C. MacQuillan, George Garas, Leon A. Adams

    Although diet‐induced weight loss is first‐line treatment for patients with nonalcoholic fatty liver disease (NAFLD), long‐term maintenance is difficult. The optimal diet for improvement in either NAFLD or associated cardiometabolic risk factors, regardless of weight loss, is unknown. We examined the effect of two ad libitum isocaloric diets (Mediterranean [MD] or low fat [LF]) on hepatic steatosis (HS) and cardiometabolic risk factors. Subjects with NAFLD were randomized to a 12‐week blinded dietary intervention (MD vs. LF). HS was determined by magnetic resonance spectroscopy (MRS). From a total of 56 subjects enrolled, 49 completed the intervention and 48 were included for analysis. During the intervention, subjects on the MD had significantly higher total and monounsaturated fat, but lower carbohydrate and sodium, intakes compared to LF subjects (P < 0.01). At week 12, HS had reduced significantly in both groups (P < 0.01), and there was no difference in liver fat reduction between groups (P = 0.32), with mean (SD) relative reductions of 25.0% (±25.3%) in LF and 32.4% (±25.5%) in MD. Liver enzymes also improved significantly in both groups. Weight loss was minimal and not different between groups (–1.6 [±2.1] kg in LF vs –2.1 [±2.5] kg in MD; P = 0.52). Within‐group improvements in Framingham Risk Score (FRS), total cholesterol, serum triglyceride (TG), and glycated hemoglobin (HbA1c) were observed in the MD (all P < 0.05), but not with the LF diet. Adherence was higher for the MD compared to LF (88% vs. 64%; P = 0.048). Conclusion: Ad libitum low‐fat and Mediterranean diets both improve HS to a similar degree.